

Europäisches Patentamt
European Patent Office
Office européen des brevets



(11) **EP 0 453 042 B1**

(12) **EUROPEAN PATENT SPECIFICATION**

(45) Date of publication and mention
of the grant of the patent:
03.11.1999 Bulletin 1999/44

(51) Int Cl.⁶: **C07D 471/04, A61K 31/505**
// (C07D471/04, 239:00, 221:00)

(21) Application number: **91200897.6**

(22) Date of filing: **16.04.1991**

(54) **Novel 2,9-disubstituted-4H-pyrido-[1,2-a]pyrimidin-4-ones**

An den Positionen 2 und 9 substituierte 4H-pyrido-(1,2-a)pyrimidin-4-one
4H-pyrido-(1,2-a)pyrimidin-4-ones substituées sur les positions 2 et 9

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IT LI LU NL SE

(30) Priority: **19.04.1990 GB 9008850**

(43) Date of publication of application:
23.10.1991 Bulletin 1991/43

(73) Proprietor: **JANSSEN PHARMACEUTICA N.V.**
2340 Beerse (BE)

(72) Inventors:
• **Kennis, Ludo Edmond Josephine**
B-2300 Turnhout (BE)
• **Vandenberk, Jan**
B-2340 Beerse (BE)
• **van Heertum, Albertus Hendricus Maria Theresia**
B-2350 Vosselaar (BE)

(74) Representative: **Wante, Dirk**
Janssen Pharmaceutica N.V.,
Patent Department,
Turnhoutseweg 30
2340 Beerse (BE)

(56) References cited:
EP-A- 0 368 388 **EP-A- 0 378 255**
US-A- 4 485 107 **US-A- 4 804 663**

- **CHEMICAL ABSTRACTS, vol. 108, no. 21, 23 May 1988 Columbus, Ohio, USA P.A.J. JANSSEN et al.: "Pharmacology of risperidone [R 64 766], a new antipsychotic with serotonin-S2 and dopamine-D2 antagonistic properties" page 54; ref. no. 179958S & J. Pharmacol. Exp. Ther. 1988, 244[2], 685-93**
- **CHEMICAL ABSTRACTS, vol. 109, no. 15, 10 October 1988 Columbus, Ohio, USA A.A.H.P. MEGENS et al.: "Differential effects of the new antipsychotic risperidone on large and small motor movements in rats: a comparison with haloperidol" page 53; ref. no. 122371M & Psychopharmacology [Berlin] 1988, 95[4], 493-6**

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

BEST AVAILABLE COPY

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

EP 0 453 042 B1


Description

[0001] In U.S. 4,804,663 and EP-0,368,388 there are described a number of 3-piperidiny-1,2-benzisoxazoles substituted with a 4H-pyrido[1,2-a]pyrimidin-4-one moiety having antipsychotic activity.

[0002] C.A. 109:122.371m (1988) discloses 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one and its anti-psychotic properties. EP-0,378,255 discloses a number of 3-piperidiny-1,2-benzisoxazoles substituted with a pyrimidopyrimidinone moiety.


[0003] The compounds of the present invention differ therefrom by the specific substitution on the 9-position of the 4H-pyrido[1,2-a]pyrimidin-4-one moiety, and their improved antipsychotic properties, in particular their utility in treating acute psychoses.

[0004] The present invention is concerned with novel 2,9-disubstituted-4H-pyrido[1,2-a]pyrimidin-4-ones having the formula



the pharmaceutically acceptable acid addition salts thereof, and the stereochemically isomeric forms thereof, wherein

Alk represents C₁₋₄alkanediyl,
D is a bicyclic heterocycle of formula



wherein

R¹ represents C₁₋₄alkyl hydroxyC₁₋₄alkyl;
each R² represents hydrogen or C₁₋₄alkyl;
R³ represents C₁₋₄alkyl, hydroxyC₁₋₄alkyl or methyl substituted with phenyl, 5-methyl-2-furanyl or 3-pyridinyl; and
R⁴ represents C₁₋₃alkyl, phenyl, 5-methyl-2-furanyl or 3-pyridinyl.

[0005] In the foregoing definitions C₁₋₄alkanediyl defines bivalent straight and branched chain alkanediyl radicals having from 1 to 4 carbon atoms such as, for example, methylene, 1,2-ethanediyl, 1,3-propanediyl, 1,4-butanediyl and the branched isomers thereof; C₁₋₃alkyl defines straight and branched chain saturated hydrocarbon radicals having from 1 to 3 carbon atoms such as, for example, methyl, ethyl, propyl, 1-methylethyl. C₁₋₄alkyl defines C₁₋₃alkyl radicals and the higher homologs thereof having 4 carbon atoms, e.g. butyl, 1-methylpropyl, 2-methylpropyl and 1,1-dimethylethyl.

[0006] An interesting subgroup within the compounds of formula (I) is formed by those compounds wherein D is a bicyclic heterocycle of formula (b) or (c).

[0007] Particular compounds are those wherein Alk is 1,2-ethanediyl, R² is methyl, R³ represents C₁₋₄alkyl, hydroxymethyl or methyl substituted with phenyl, 5-methyl-2-furanyl or 3-pyridinyl; and R⁴ is C₁₋₃alkyl, phenyl, 5-methyl-2-furanyl or 3-pyridinyl.

[0008] Another particularly interesting subgroup within the compounds of formula (I) is formed by those compounds

wherein D is a bicyclic radical of formula (a).


[0009] Particular compounds are those compounds of formula (I) wherein Alk is 1,2-ethanediyl, 1,3-propanediyl or 1,4-butanediyl; and/or R² is hydrogen or methyl.

[0010] More particular compounds within the invention are those particular compounds wherein Alk is 1,2-ethanediyl; and/or R¹ is C₁₋₄alkyl, especially methyl.

[0011] The most interesting compounds within the invention are selected from the group consisting of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one and the pharmaceutically acceptable acid addition salt forms thereof.

[0012] The compounds of this invention may have an asymmetric carbon atom in their structure. The absolute configuration of such a centre may be indicated by the stereochemical descriptors R and S, this R and S notation corresponding to the rules described in Pure Appl. Chem. 1976, 45, 11-30. Unless otherwise mentioned or indicated, the chemical designation of compounds denotes the mixture of all possible stereochemically isomeric forms, said mixtures containing all diastereomers and enantiomers of the basic molecular structure. Stereochemically isomeric forms of the compounds of formula (I) are obviously intended to be embraced within the scope of the invention.


[0013] The compounds of formula (I) can generally be prepared by N-alkylating a 3-piperidinyl-1,2-benzisoxazole of formula (II) with an alkylating reagent of formula (III) following art-known N-alkylation procedures.



[0014] In formula (III) W represents an appropriate reactive leaving group such as, for example, halo, e.g. chloro, bromo or iodo; sulfonyloxy, e.g. methanesulfonyloxy, trifluoromethanesulfonyloxy, benzenesulfonyloxy, 4-methylbenzenesulfonyloxy and the like leaving groups. In case R¹ represents hydroxyc₁₋₄alkyl, the hydroxyl group may be protected by a protective group such as, for example, phenylmethyl, trimethylsilyl, tert. butyldimethylsilyl and the like. Said N-alkylation reaction can conveniently be carried out by mixing the reactants, optionally in a reaction-inert solvent such as, for example, water; an aromatic solvent, e.g. benzene, methylbenzene, dimethylbenzene, chloro-benzene, methoxybenzene and the like; a C₁₋₆alkanol, e.g. methanol, ethanol, 1-butanol and the like; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like; an ester, e.g. ethyl acetate, γ -butyrolactone and the like; an ether, e.g. 1,1'-oxybisethane, tetrahydrofuran, 1,4-dioxane and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, N,N-dimethylacetamide, dimethylsulfoxide, pyridine, 1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)-pyrimidinone, 1,3-dimethyl-2-imidazolidinone, 1,1,3,3-tetramethylurea, 1-methyl-2-pyrrolidinone, nitrobenzene, acetonitrile and the like; or a mixture of such solvents. The addition of an appropriate base such as, for example, an alkali metal or an earth alkaline metal carbonate, hydrogen carbonate, hydroxide, oxide, carboxylate, alkoxide, hydride or amide, e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, calcium oxide, sodium acetate, sodium methoxide, sodium hydride, sodium amide and the like, or an organic base such as, for example, a tertiary amine, e.g. N,N-diethylethanamine, N-(1-methylethyl)-2-propanamine, 4-ethylmorpholine, 1,4-diazabicyclo[2.2.2]octane, pyridine and the like, may optionally be used to pick up the acid which is formed during the course of the reaction. In some instances the addition of an iodide salt, preferably an alkali metal iodide, or a crown ether, e.g. 1,4,7,10,13,16-hexaoxacyclooctadecane and the like, may be appropriate. Stirring and somewhat elevated temperatures may enhance the rate of the reaction; more in particular the reaction may be conducted at the reflux temperature of the reaction mixture. Additionally, it may be advantageous to conduct said N-alkylation under an inert atmosphere such as, for example, oxygen-free argon or nitrogen gas. Alternatively, said N-alkylation may be carried out by applying art-known conditions of phase transfer catalysis reactions. Said conditions comprise stirring the reactants, with an appropriate base and optionally under an inert atmosphere as defined hereinabove, in the presence of a suitable phase transfer catalyst such as, for example, a trialkylphenylmethylammonium, tetraalkylammonium, tetraalkylphosphonium, tetraarylphosphonium halide, hydroxide, hydrogen sulfate and the like catalysts. Somewhat elevated temperatures may be appropriate to enhance the rate of the reaction. In case R¹ represents a protected hydroxyc₁₋₄alkyl group, the hydroxyl group may be deprotected following art-known methods such as hydrogenolysis or hydrolysis.


[0015] In this and the following preparations, the reaction products may be isolated from the medium and, if necessary, further purified according to methodologies generally known in the art such as, for example, extraction, crystallization, trituration and chromatography.

[0016] The compounds of formula (I) can conveniently be obtained by the cyclization of an oxime of formula (IV), wherein Y represents a reactive leaving group such as, for example, halo or nitro. Preferably Y represents a halo group and more particularly fluoro.



[0017] Said cyclization reaction of the oxime of formula (IV) may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent at temperatures in the range of 20° to 200°C, preferably at 50° to 150°C, and in particular at the reflux temperature of the reaction mixture. Or, if desirable, said base may first be added, preferably at room temperature, whereupon the thus formed oxime salt is cyclized, preferably at an increased temperature and more preferably at the reflux temperature of the reaction mixture. Appropriate bases for said cyclization are, for example, alkali and earth alkaline metal carbonates, hydrogen carbonates, hydroxides, alkoxides or hydrides, e.g. sodium carbonate, sodium hydrogen carbonate, potassium carbonate, sodium hydroxide, sodium methoxide, sodium hydride or organic bases such as amines, e.g. *N,N*-diethylethanamine, 4-ethylmorpholine and the like bases. Suitable solvents are, for example, water; aromatic hydrocarbons, e.g. benzene, methylbenzene, dimethylbenzene and the like; halogenated hydrocarbons, e.g. dichloromethane, trichloromethane, 1,2-dichloroethane and the like; lower alkanols, e.g. methanol, ethanol, 1-butanol and the like; ketones, e.g. 2-propanone, 4-methyl-2-pentanone and the like; ethers, e.g. 1,4-dioxane, tetrahydrofuran and the like; dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide, dimethylsulfoxide, 1-methyl-2-pyrrolidinone and the like, or mixtures of such solvents.

[0018] The compounds of formula (I) can also be obtained by cyclizing an activated oxime derivative of formula




wherein -O-L represents a reactive leaving group and L is an acid residue and more particularly is formyl, (C_{1-6} alkyl or aryl)carbonyl, e.g. acetyl, propionyl, benzoyl and the like; (C_{1-6} alkyl or aryl)oxycarbonyl, e.g. methoxycarbonyl, ethoxycarbonyl, (1,1-dimethyl)ethoxycarbonyl, phenyloxycarbonyl and the like; (C_{1-6} alkyl or aryl)sulfonyl, e.g. methanesulfonyl, benzenesulfonyl, 4-methylbenzenesulfonyl, 2-naphthalenesulfonyl and the like; *N*-acylaminocarbonyl, e.g. trichloromethylcarbonylaminocarbonyl and the like. Said cyclization reaction of the activated oxime derivative of formula (V) may conveniently be conducted by treatment with an appropriate base, preferably in a suitable reaction-inert solvent, at temperatures in the range from 20° to 200°C, particularly from 50° to 150°C and preferably at the reflux temperature of the reaction mixture. In some instances however, it may be advantageous not to add a base to the reaction mixture and to remove the acid liberated during the reaction by distillation at normal pressure or, if desired, at reduced pressure. Alternatively, said cyclization may also be effected by heating the oxime derivative (V) in vacuo without a solvent.

[0019] Appropriate bases are for example, alkali and earth alkaline metal carbonates, hydrogen carbonates and organic amines, e.g. sodium carbonate, potassium carbonate, sodium hydrogen carbonate, *N,N*-diethylethanamine, 4-ethylmorpholine, 1,4-diazabicyclo-[2.2.2]octane, pyridine and the like bases. Suitable solvents for said cyclization are, for example, aromatic hydrocarbons, e.g. benzene, methylbenzene, dimethylbenzene and the like; ethers, e.g. 1,1'-oxybisethane, 1,1'-oxybisbutane, tetrahydrofuran, 1,4-dioxane, 1,1'-oxybis[2-methoxyethane], 2,5,8,11-tetraoxadodecane and the like; dipolar aprotic solvents, e.g. *N,N*-dimethylformamide, *N,N*-dimethylacetamide, 1-methyl-2-pyrrolidinone, hexamethylphosphoric triamide, pyridine, acetic anhydride and the like; halogenated hydrocarbons, e.g. trichloromethane, tetrachloromethane, 1,2-dichloroethane, chlorobenzene and the like solvents.

[0020] The compounds of formula (I) wherein D is a bicyclic heterocycle of formula (a), said compounds being represented by formula (I-a), can also be prepared following art-known cyclization procedures for preparing pyrimidin-4-ones such as, for example, by reacting an aminopyridine of formula (VII) with a β -dicarbonyl intermediate of formula

(VIII), or by cyclizing a reagent of formula (IX) with an enamine of formula (X). In formulae (VIII), (IX) and (X) R^5 represents an appropriate reactive leaving group such as, for example, C_{1-6} alkyloxy, hydroxy, halo, amino, mono- or di- $(C_{1-6}$ alkyl)amino and the like.




[0021] Said cyclization reactions may generally be carried out by stirring the reactants, optionally in the presence of a suitable reaction-inert solvent such as, for example, an aliphatic, alicyclic or aromatic hydrocarbon, e.g. hexane, cyclohexane, benzene and the like; pyridine, *N,N*-dimethylformamide and the like dipolar aprotic solvents. In order to enhance the rate of the reaction it may be appropriate to increase the temperature, more particularly, it may be recommendable to carry out the reaction at the reflux temperature of the reaction mixture.

[0022] The compounds of formula (I) have basic properties and, consequently, they may be converted to their therapeutically active non-toxic acid addition salt forms by treatment with appropriate acids, such as, for example, inorganic acids, such as hydrohalic acid, e.g. hydrochloric, hydrobromic acid and the like, sulfuric acid, nitric acid, phosphoric acid and the like; or organic acids, such as, for example, acetic, propanoic, hydroxyacetic, 2-hydroxypropanoic, 2-oxopropanoic, ethanedioic, propanedioic, butanedioic, (Z)-2-butenedioic, (E)-2-butenedioic, 2-hydroxybutanedioic, 2,3-dihydroxybutanedioic, 2-hydroxy-1,2,3-propanetricarboxylic, methanesulfonic, ethanesulfonic, benzenesulfonic, 4-methylbenzenesulfonic, cyclohexanesulfamic, 2-hydroxybenzoic, 4-amino-2-hydroxybenzoic and the like acids. Conversely the salt form can be converted into the free base form by treatment with alkali.

[0023] The term acid addition salt as used hereinabove also comprises the solvates which the compounds of formula (I) are able to form and said solvates are meant to be included within the scope of the present invention. Examples of such solvates are e.g., the hydrates, alcoholates and the like.

[0024] Some of the intermediates and starting materials for use in the foregoing preparations are known compounds, while others are novel. Some intermediates of formula (II) and methods of preparing them are known from U.S. 4,804,663. The alkylating reagents of formula (III) are novel and can be prepared according to art-known methodologies of preparing similar compounds and will be described hereinafter in more detail.


[0025] By condensing an optionally protected 2-aminopyridine derivative (VII) with an α -acyl lactone (XI) in the presence of an activating reagent in a suitable reaction-inert solvent, an intermediate of formula (III-a) can be obtained.



[0026] In the formulae (VII), (III-a) and hereinafter whenever expedient, R^1 may be protected by a protective group


which can be readily removed such as, for example, a hydrogenolyzable group, e.g. phenylmethyl and the like; a hydrolyzable group, e.g. methyl, trimethylsilyl, tert. butyldimethylsilyl and the like. Appropriate activating reagents for said condensation reaction typically are halogenating reagents such as, for example, phosphoryl chloride, phosphoryl bromide, phosphorous trichloride, thionyl chloride and the like reagents.

[0027] Said intermediates of formula (III-a) can also be obtained by condensing an optionally protected 2-aminopyridine (VII) with a reagent of formula (XII), in the presence of a base in a suitable reaction-inert solvent and subsequently converting the protected alcohol group into a reactive leaving group.




[0028] In (XII) P is a readily removable protective group such as, for example an acetal, e.g. a tetrahydropyranyl group and the like protective groups. Said condensation reaction can conveniently be conducted in a solvent such as an alkanol, e.g. methanol, ethanol and the like, a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like, an aromatic hydrocarbon, e.g. benzene, methylbenzene and the like. Suitable bases are alkali and earth alkaline metal carbonates, oxides, hydroxides, hydrides or alkoxides, e.g. sodium carbonate, sodium hydroxide, potassium hydroxide, sodium hydride, sodium methoxide, potassium tert. butoxide and the like. Subsequently the protective group P is easily removed by acid hydrolysis and the hydroxy group is converted into a leaving group by reaction with a hydrohalic acid, e.g. hydrochloric or hydrobromic acid, a halogenating reagent, e.g. thionyl chloride, phosphorous trichloride, phosphoryl chloride, phosphorous tribromide and the like, a sulfonylating reagent, e.g. methanesulfonyl chloride, methylbenzenesulfonyl chloride and the like.


[0029] Some of the starting materials of formula (III-b) are known and can be prepared according to the procedures described in U.S. Pat. No. 4,485,107. The intermediates of formula (III-b) can also be prepared conveniently from an intermediate of formula (XIII) by condensation with an appropriate aldehyde in the presence of a catalyst such as a Lewis acid, in particular 4-methylbenzenesulfonic acid, in a suitable solvent such as an aromatic hydrocarbon e.g. methylbenzene, dimethylbenzene and the like. The thus obtained intermediate of formula (III-c) can easily be reduced to the intermediates of formula (III-b) by reduction, in particular catalytic hydrogenation.



[0030] The intermediates of formula (IV) may be prepared by N-alkylating a reagent of formula (III) with an oxime derivative of formula (XIV) following the same procedures as described hereinabove for the preparation of the compounds of formula (I) from the intermediates (II) and (III). The derivatives (XIV) are known from U.S. -4,804,663.




[0031] The intermediates of formula (V) may be obtained by reacting an oxime of formula (XV) with an activated acid derivative of formula L-W¹,



wherein L is an acid residue as defined hereinabove and W¹ represents a reactive leaving group such as, for example, halo, (aryl or C₁₋₆alkyl)carbonyloxy, (aryl or C₁₋₆alkyl)-oxy and the like. As typical examples of such reagents there may be mentioned carboxylic acid anhydrides, e.g. acetic anhydride, benzoic anhydride and the like; carboxylic acid halides, e.g. acetyl chloride, benzoyl chloride and the like; carbonochloridates, e.g. methyl, ethyl or phenyl carbonochloridate and the like; di(C₁₋₆alkyl)-carbonates, e.g. dimethylcarbonate, diethylcarbonate and the like. The reaction of the intermediates (XIV) with said activated acid derivatives may be carried out following art-known esterification procedures, e.g. by stirring the reactants at a somewhat elevated temperature, preferably in a reaction-inert solvent such as, for example, an aromatic hydrocarbon, e.g. benzene, methylbenzene and the like; a halogenated hydrocarbon, e.g. dichloromethane, trichloromethane and the like; a ketone, e.g. 2-propanone, 4-methyl-2-pentanone and the like; an ether, e.g. 1,1'-oxybisethane, 1,4-dioxane and the like; a dipolar aprotic solvent, e.g. N,N-dimethylformamide, pyridine and the like solvents. In some instances it may be appropriate to add a suitable base such as, for example, N,N-diethylethanamine, N-(1-methylethyl)-2-propanamine, 4-ethylmorpholine, N,N-dimethyl-4-aminopyridine and the like bases to the reaction mixture.

[0032] The intermediate of formula (XV) in turn may be prepared by N-alkylating a reagent of formula (III) with an oxime derivative of formula (XVI)



following the same procedures as described hereinabove for the preparation of the compounds of formula (I) from the intermediates (II) and (III).

[0033] The compounds of formula (I) and some of the intermediates in the present invention may contain an asymmetric carbon atom. Pure stereochemically isomeric forms of said compounds and said intermediates can be obtained by the application of art-known procedures. For example, diastereoisomers can be separated by physical methods such as selective crystallization or chromatographic techniques, e.g. counter current distribution, liquid chromatography and the like methods. Enantiomers can be obtained from racemic mixtures by first converting said racemic mixtures with suitable resolving agents such as, for example, chiral acids, e.g. tartaric, malic and mandelic acids, camphor sulfonic acid, 4,5-dihydro-1H-2-benzopyran-2-carboxylic acid and the like, to mixtures of diastereomeric salts or compounds; then physically separating said mixtures of diastereomeric salts or compounds by, for example, selective

crystallization or chromatographic techniques, e.g. liquid chromatography and the like methods; and finally converting said separated diastereomeric salts or compounds into the corresponding enantiomers by hydrolysis.

[0034] Pure stereochemically isomeric forms of the compounds of formula (I) may also be obtained from the pure stereochemically forms of the appropriate intermediates and starting materials, provided that the intervening reactions occur stereospecifically. The pure and mixed stereochemically isomeric forms of the compounds of formula (I) are intended to be embraced within the scope of the present invention.

[0035] The compounds of formula (I), the pharmaceutically acceptable acid addition salts and stereochemically isomeric forms thereof, are potent antagonists of neurotransmitters and in particular of dopamine. Antagonizing said neurotransmitter suppresses a variety of phenomena induced by the release, in particular the excessive release, of dopamine. Central dopamine receptor antagonists are known to have neuroleptic properties, for example, they counteract the positive symptoms of schizophrenia, e.g. hallucinations, delusional thinking, severe excitement and unusual behaviour. Therapeutic indications for using the present compounds therefore are mainly in the CNS area, particularly as potent antipsychotic agents and especially as agents useful in treating acute psychoses. The present compounds are particularly effective in treating psychiatric patients suffering from severe agitation and in need of rapid re-stabilization. Surprisingly, the present compounds are further found to be efficacious in treating patients not responding or responding poorly to administration of other neuroleptics such as haloperidol or risperidone. The present compounds also show central serotonin antagonism. Central acting serotonin antagonists appear to improve the negative symptoms of schizophrenia, e.g. anergy, apathy, social withdrawal and depressive mood, and also appear to reduce the incidence of extrapyramidal side-effects during maintenance therapy with classical neuroleptics, i.e. dopamine antagonists. Combined dopamine-serotonin antagonists are especially interesting as they offer relief of both the positive and negative symptoms of schizophrenia.

[0036] The compounds of formula (I) show the additional advantage of also being long acting dopamine antagonists. The potency and long duration of action of the present compounds can easily be demonstrated in a number of *in vivo* tests. For example, the compounds of the present invention inhibit and/or block phenomena or symptoms induced by the dopamine antagonists apomorphine and amphetamine in rats and dogs at low dosages for a relatively long period of time. Hence these compounds only need to be administered at relatively large intervals, the actual time of administration depending on the nature of the compound of formula (I) and on the severity of the condition of the subject to be treated. As a consequence, the present compounds allow for a more efficient therapy and in particular are suitable for intervention in severe, acute situations where a rapid, profound and lasting antipsychotic effect is desired so as to control and re-stabilize the patient. Further advantages of the present compounds are the excellent bioavailability upon oral administration and the rapid onset of action (<1h).

[0037] In view of their useful pharmacological properties, the subject compounds may be formulated into various pharmaceutical forms for administration purposes. To prepare the pharmaceutical compositions of this invention, an effective amount of the particular compound, in acid addition salt or base form, as the active ingredient is combined in intimate admixture with a pharmaceutically acceptable carrier, which may take a wide variety of forms depending on the form of preparation desired for administration. These pharmaceutical compositions are desirably in unitary dosage form suitable, preferably, for administration orally, rectally, percutaneously, or by parenteral injection. For example, in preparing the compositions in oral dosage form, any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets. Because of their ease in administration, liquid preparations are especially suited for the treatment of patients during the initial, acute phase of their agitation. On the other hand, during maintenance therapy, tablets and capsules represent the most advantageous oral dosage unit form, in which case solid pharmaceutical carriers are obviously employed. For parenteral compositions, the carrier will usually comprise sterile water, at least in large part, though other ingredients, for example, to aid solubility, may be included. Injectable solutions, for example, may be prepared in which the carrier comprises saline solution, glucose solution or a mixture of saline and glucose solution. Injectable solutions containing compounds of formula (I) may also be formulated in an oil for prolonged action. Appropriate oils for this purpose are, for example, peanut oil, sesame oil, cottonseed oil, corn oil, soy bean oil, synthetic glycerol esters of long chain fatty acids and mixtures of these and other oils. Injectable suspensions may also be prepared in which case appropriate liquid carriers, suspending agents and the like may be employed. In the compositions suitable for percutaneous administration, the carrier optionally comprises a penetration enhancing agent and/or a suitable wettable agent, optionally combined with suitable additives of any nature in minor proportions, which additives do not cause any significant deleterious effects on the skin. Said additives may facilitate the administration to the skin and/or may be helpful for preparing the desired compositions. These compositions may be administered in various ways, e.g., as a transdermal patch, as a spot-on or as an ointment. Acid addition salts of (I) due to their increased water solubility over the corresponding base forms, may obviously be more suitable in the preparation of aqueous compositions.

[0038] It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit

form for ease of administration and uniformity of dosage. Dosage unit form as used in the specification and claims herein refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.

[0039] In view of the usefulness of the subject compounds in the treatment of diseases associated with the release of neurotransmitters, in particular in the treatment of psychotic diseases, it is evident that the present invention provides a method of treating warm-blooded animals suffering from such diseases, in particular psychotic diseases, said method comprising the systemic administration of an antipsychotic amount of a compound of formula (I) or a pharmaceutically acceptable acid addition salt thereof, effective in treating diseases associated with the release of neurotransmitters, in particular psychotic diseases. Those of skill in the treatment of such diseases could easily determine the effective amount from the test results presented hereinafter. In general it is contemplated that an effective antipsychotic amount would be from about 0.0025 to about 4 mg/kg body weight, preferably from about 0.01 mg/kg to about 1 mg/kg body weight, more preferably from about 0.02 mg/kg to about 0.10 mg/kg body weight. The required dose may advantageously be administered as two, three or more sub-doses at appropriate intervals throughout the day. Said subdoses may be formulated as unit dosage forms, for example containing 0.25 to 5 mg, in particular 0.5 to 2 mg of active ingredient per unit dosage form.

[0040] The following examples are intended to illustrate the present invention. Unless otherwise stated all parts therein are by weight.

EXPERIMENTAL PART

A. Preparation of the intermediates

Example 1

[0041]

a) To a solution of 6.2 parts of 2-amino-3-pyridinemethanol in 23.5 parts of N,N-dimethylformamide there were added 6.8 parts of 1H-imidazole and 7.5 parts of chlorodimethyl(1,1-dimethylethyl)silane. The whole was cooled for 10 min in an icebath and was stirred overnight at room temperature. The reaction mixture was diluted with 100 parts of water and the product was extracted with 1,1'-oxybisethane (2x). The combined extracts were washed with water and NaCl (sat.), dried, filtered and evaporated, yielding 11.1 parts (93.1%) of 3-[[dimethyl(1,1-dimethylethyl)silyloxy]-methyl]-2-pyridinamine (interm. 1).

b) A mixture of 5.5 parts of intermediate (1), 4.93 parts of dihydro-3-(1-oxoethyl)-2(3H)-furanone, a pinch of 4-methylbenzenesulfonic acid and 34.4 parts of a mixture of xylenes was stirred for 18 hours at reflux temperature using a water separator. After cooling, there were added 26.1 parts of methylbenzene. The whole was washed successively with water, sodium hydrogen sulfite and NaCl (sat.), and was then dried, filtered and evaporated. The residue was stirred in hexane. The solvent was decanted and, after cooling in a mixture of ethanol and dry ice, the precipitate was filtered off and dried, yielding 6.1 parts (68.1%) of 3-[1-[[3-[[dimethyl(1,1-dimethylethyl)silyloxy]-methyl]-2-pyridinyl]amino]ethylidene]dihydro-2(3H)-furanone (interm. 2).

c) To a stirred mixture of 2.5 parts of aluminum chloride and 189 parts of 1,2-dichloroethane there were added 5.4 parts of intermediate (2). After heating for 1/2 hour at 90°C and subsequent cooling, there were added 599 parts of dichloromethane and 50 parts of water. The whole was filtered and the organic layer of the filtrate was separated, dried, filtered and evaporated. The residue was dissolved in 149 parts of trichloromethane and this solution was washed with NaCl (sat.), dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CHCl₃ / hexane / CH₃OH 48:50:2). The eluent of the pure fractions was evaporated, yielding 3.0 parts of product. The less pure fractions were chromatographed again (silica gel; CHCl₃ / CH₃OH 99:1), yielding an additional 1.75 parts of product. The combined crops were crystallized from hexane, yielding 2.91 parts (53.8%) of 9-[[dimethyl(1,1-dimethylethyl)silyloxy]methyl]-3-(2-hydroxyethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (interm. 3).

d) To a cooled (salt / ice-bath) mixture of 0.348 parts of intermediate (3) and 0.98 parts of pyridine there was added a solution of 0.115 parts of methanesulfonyl chloride in 0.196 parts of pyridine. The mixture was left for 1/2 hour to reach 0°C and was further stirred for 20 hours at 4°C. There were added 0.084 parts of NaHCO₃ while cooling on ice. Stirring was continued for 1 1/2 hour and then the whole was filtered. The precipitate was rinsed with 1,1'-oxybisethane and the combined filtrates were evaporated. This residue was used without further purification. Theoretical yield : 0.43 parts (100%) of 9-[[dimethyl(1,1 -dimethylethyl)silyloxy]methyl]-2-methyl-4-oxo-4H-pyrido

[1,2-a]pyrimidin-3-ethanol methanesulfonate(ester) (interm. 4).

e) A mixture of 0.426 parts of intermediate (4), 0.257 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole monohydrochloride, 3.95 parts of methanol and 0.404 parts of N-(1-methylethyl)-2-propanamine was stirred for 68 hours at 60°C. The reaction mixture was evaporated and the residue was partitioned between trichloromethane and water. The organic layer was separated, washed with NaCl (sat.), dried, filtered and evaporated. The residue was purified by column chromatography (silica gel; CHCl₃ / CH₃OH 96:4). The eluent of the desired fraction was evaporated, yielding 0.319 parts (57.9%) of 9-[[dimethyl(1,1-dimethylethyl)silyloxy]methyl]-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one (interm. 5).

Example 2

[0042] To a mixture of 53 parts of (Z)-(2,4-difluorophenyl) (4-piperidinyl)methanone, oxime monohydrochloride and 43.5 parts of 3-(2-chloroethyl)-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one in 160 parts of methanol there were added 72 parts of N-(1-methylethyl)-2-propanamine. After stirring for 44 hours at 60°C, the reaction mixture was diluted with 54 parts of water. At room temperature the precipitate was filtered off, washed with water and dried in vacuo at 50°C, yielding 78.3 parts (98.8%) of (Z)-3-[2-[4-[(2,4-difluorophenyl)(hydroxyimino)methyl]-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one (interm. 6).

Example 3

[0043]

a) To a solution of 5.67 parts of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one in 43 parts of xylene there were added 2.65 parts of benzaldehyde and 0.7 parts of 4-methylbenzenesulfonic acid. The whole was refluxed for 8 hours using a water separator. After cooling, the precipitate was filtered off and crystallized from 2-propanol, yielding 2.4 parts (30.5%) of product. The mother liquor was evaporated and the residue was purified by column chromatography (silica gel; CHCl₃ / CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was crystallized from 2-propanol, yielding an additional 2 parts (25.4%) of product. Total yield : 4.4 parts (55.9%) of (E)-3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-(phenylmethylene)-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 130.8°C (interm. 7).

[0044] In a similar manner there were also prepared :

(E)-3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-[(5-methyl-2-furanyl)methylene]-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 133.1°C (interm. 8);

(E)-9-butylidene-3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 76.6°C (interm. 9); and

(E)-3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-(3-pyridinylmethylene)-4H-pyrido[1,2-a]pyrimidin-4-one; (interm. 10)

b) A mixture of 3.14 parts of intermediate 7 and 79 parts of methanol was hydrogenated at normal pressure and room temperature with 1 part of platinum-on-charcoal catalyst 5%. After the calculated amount of hydrogen was taken up, the catalyst was filtered off and the filtrate was evaporated. The residue was converted into the monohydrochloride salt in 2-propanol, yielding 2.1 parts (59.4%) of 3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-9-(phenylmethyl)-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride; mp. 181.4°C (interm. 11).

In a similar manner there was also prepared :

(±)-9-butyl-3-(2-chloroethyl)-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one monohydrochloride; mp. 175.9°C (interm. 12).

B. Preparation of the final compounds

Example 4

[0045] A mixture of 4.8 parts of 3-(2-bromoethyl)-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one, 3.9 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole monohydrochloride, 10 parts of sodium carbonate, a few crystals of potassium iodide and 144 parts of 4-methyl-2-pentanone was stirred overnight at room temperature. After cooling, the reaction mixture was poured into water. The organic layer was separated, dried, filtered and evaporated. The residue was

purified by column chromatography (silica gel ; CH₂Cl₂ / CH₃OH 95:5). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile, yielding 3 parts (47.6%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 199.9°C (comp. 1).

In a similar manner there was also prepared :

- 5 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 171.8°C (comp. 2)

Example 5

- 10 **[0046]** A mixture of 78 parts of intermediate (6), 580 parts of methylbenzene and 25 parts of potassium hydroxide in 260 parts of water was stirred for 1/2 hour at 45-55°C and for 3 hours at reflux temperature. After cooling, the organic layer was separated and left to crystallized while cooling on ice. The product was filtered off, washed with methylbenzene and dried at 50°C in vacuo, yielding 47.7 parts (80%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one (comp. 1).

Example 6

[0047]

- 20 a) To a solution of 0.806 parts of intermediate (5) in 8.9 parts of tetrahydrofuran there were added 1.46 parts of a tetrabutylammonium fluoride solution in tetrahydrofuran 1M. After stirring for 45 min at room temperature, the reaction mixture was evaporated and the residue was diluted with 5 parts of water. The crystallized product was filtered off, washed with water (5x) and 2,2'-oxybispropane (5x) and dissolved in trichloromethane. This solution was washed with NaOH 1N and water and was then filtered. The filtrate was evaporated and the residue was
25 boiled in 2-propanol. The product was filtered off at room temperature and dried in vacuo at 75°C for 4 hours, yielding 0.348 parts (54.4%) of 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-9-(hydroxymethyl)-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 185.6°C (comp. 3).

Example 7

- 30 **[0048]** A mixture of 3.14 parts of intermediate (7), 2.2 parts of 6-fluoro-3-(4-piperidinyl)-1,2-benzisoxazole, 2.65 parts of sodium carbonate, 94 parts of N,N-dimethylformamide and 0.1 part of potassium iodide was stirred overnight at 80-90°C. The reaction mixture was poured into water and the product was extracted with methylbenzene. The extract was dried, filtered and evaporated. The residue was purified by column chromatography (silica gel ; CHCl₃ / CH₃OH
35 90:10). The eluent of the desired fraction was evaporated and the residue was crystallized from acetonitrile. The product was filtered off and dried, yielding 3.5 parts (70.2%) of (E)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-(phenylmethylene)-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 160.5°C (comp. 4).
In a similar manner there were also prepared :

- 40 (E)-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-[(5-methyl-2-furanyl)methylene]-4H-pyrido[1,2-a]pyrimidin-4-one;
mp. 190.0°C (comp. 5);
3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-(phenylmethyl)-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 140.1°C (comp. 6);
45 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-9-(3-pyridinylmethylene)-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 190.4°C (comp. 7);
(E)-9-butyldiene-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido[1,2-a]pyrimidin-4-one; mp. 144.7°C (comp. 8); and
(±)-9-butyl-3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-4H-pyrido
50 [1,2-a]pyrimidin-4-one; mp. 115.7°C (comp. 9);

C. Pharmacological Examples

- 55 **[0049]** The long acting, central dopamine antagonism of the present compounds can be demonstrated in a number of relevant pharmacological tests such as, for example, the "Apomorphine antagonism in rats" test, the "Amphetamine antagonism in rats" test and the "Apomorphine antagonism test in dogs" test.

Example 8 : Apomorphine antagonism in rats

[0050] The test procedure is described in Arch. Int. Pharmacodyn. Ther. 227, 238-253 (1977) and demonstrates the central dopamine antagonistic activity of the tested compounds of formula (I) by preventing apomorphine (1.25 mg/kg iv) induced agitation and stereotypy such as compulsive sniffing, licking and chewing in rats. In Table 1 are listed the ED₅₀ values (mg/kg) for inhibition of apomorphine-induced symptoms obtained with compound (1) and the subsequent apomorphine challenge at different intervals (time).

Table 1

| Time | ED ₅₀ (mg/kg) for inhibition |
|------|---|
| 0.5 | 0.021 |
| 1 | 0.018 |
| 2 | 0.032 |
| 4 | 0.068 |
| 8 | 0.29 |

Example 9 : Amphetamine antagonism in rats

[0051] This test procedure is described in Industrial Pharmacology, Part II, Antidepressants, eds, S. Fielding and H. Lal, p. 125-141, Futura Publishing Company (1975). Solvent (controls) or the test compound (1) were injected sc, followed after 45 min by amphetamine (2.5 mg/kg, sc). Starting 15 min after the amphetamine injection, agitation and consumption of oxygen were evaluated every 15 min over a period of 1 hour. Agitation was scored 3 (pronounced), 2 (moderate), 1 (slight) and 0 (absent), the total score maximally being 4 x 3 = 12. Oxygen consumption was measured on a mercury manometer simultaneously. Significant inhibition required a total score for agitation of less than 11 (0.3% in controls) or a final scale reading for oxygen consumption of less than 105 Hg units (1.8% in controls; mean = 118 units). Blockade of amphetamine-induced agitation was considered complete at a total score of less than 4 and that of oxygen consumption at a scale reading of less than 90 Hg units (i.e. the agitation score and oxygen consumption level of normal rats which is never observed in amphetamine-treated controls). Listed are the ED₅₀ values (mg/kg) obtained with compound (1) and the subsequent amphetamine challenge.

| Amphetamine antagonism | Inhibition | Blockade |
|-------------------------|------------|----------|
| Agitation | 0.014 | 0.064 |
| Oxygen hyperconsumption | 0.057 | 0.19 |

Example 10 : Apomorphine antagonism in dogs

[0052] This test is described in Psychopharmacol. 78, 210-213 (1982) and provides - besides a measure of the potency - a good measure of the duration of action of the tested compounds as dopamine antagonists. Apomorphine (0.31 mg/kg, sc ; 4 times the ED₉₅) induced emesis in all control dogs. At different time intervals before the apomorphine challenge, the dogs were pretreated with different doses (iv, sc or po) of the test compound (1). Complete absence of emesis for 1 hour after the challenge was adopted as the criterion for apomorphine antagonism in dogs. Listed are the ED₅₀ values (mg/kg) obtained with compound (1) at different intervals after iv, sc or po administration.

| Time (h) | ED ₅₀ (iv) | ED ₅₀ (sc) | ED ₅₀ (po) |
|----------|-----------------------|-----------------------|-----------------------|
| 0.5 | 0.0012 | 0.0045 | 0.0050 |
| 1 | 0.0011 | 0.0024 | 0.0015 |
| 2 | 0.0012 | 0.0014 | 0.00089 |
| 4 | 0.00079 | 0.00089 | 0.0012 |
| 8 | 0.00089 | 0.0012 | 0.00099 |
| 16 | 0.0012 | 0.0022 | 0.0024 |
| 32 | 0.0029 | 0.0045 | 0.0063 |

D. Composition Examples

[0053] The following formulations exemplify typical pharmaceutical compositions in dosage unit form suitable for systemic or topical administration to warm-blooded animals in accordance with the present invention.

[0054] "Active ingredient" (A.I.) as used throughout these examples relates to a compound of formula (I), a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof.

Example 11 : Oral drops

[0055] 50 g of the A.I. is dissolved in 0.5 l of 2-hydroxypropanoic acid and 1.5 l of the polyethylene glycol at 60~80°C. After cooling to 30~40°C there are added 35 l of polyethylene glycol and the mixture is stirred well. Then there is added a solution of 1750 g of sodium saccharin in 2.5 l of purified water and while stirring there are added 2.5 l of cocoa flavor and polyethylene glycol q.s. to a volume of 50 l, providing an oral drop solution comprising 1 mg/ml of the A.I. The resulting solution is filled into suitable containers.

Example 12 : Oral solution

[0056] 9 g of methyl 4-hydroxybenzoate and 1 g of propyl 4-hydroxybenzoate are dissolved in 4 l of boiling purified water. In 3 l of this solution are dissolved first 10 g of 2,3-dihydroxybutanedioic acid and thereafter 8 g of the A.I. The latter solution is combined with the remaining part of the former solution and 12 l of 1,2,3-propanetriol and 3 l of sorbitol 70% solution are added thereto. 40 g of sodium saccharin are dissolved in 0.5 l of water and 2 ml of raspberry and 2 ml of gooseberry essence are added. The latter solution is combined with the former, water is added q.s. to a volume of 20 l providing an oral solution comprising 2 mg of the A.I. per teaspoonful (5 ml). The resulting solution is filled in suitable containers.

Example 13: Capsules

[0057] 2 g of the A.I., 6 g sodium lauryl sulfate, 56 g starch, 56 g lactose, 0.8 g colloidal silicon dioxide, and 1.2 g magnesium stearate are vigorously stirred together. The resulting mixture is subsequently filled into 1000 suitable hardened gelatin capsules, each comprising 2 mg of the A.I..

Example 14 : Film-coated tabletsPreparation of tablet core

[0058] A mixture of 10 g of the A.I., 570 g lactose and 200 g starch is mixed well and thereafter humidified with a solution of 5 g sodium dodecyl sulfate and 10 g polyvinylpyrrolidone (Kollidon-K 90®) in about 200 ml of water. The wet powder mixture is sieved, dried and sieved again. Then there are added 100 g microcrystalline cellulose (Avicel®) and 15 g hydrogenated vegetable oil (Sterotex®). The whole is mixed well and compressed into tablets, giving 10.000 tablets, each comprising 1 mg of the active ingredient.

Coating


[0059] To a solution of 10 methyl cellulose (Methocel 60 HG®) in 75 ml of denaturated ethanol there is added a solution of 5 g of ethyl cellulose (Ethocel 22 cps®) in 150 ml of dichloromethane. Then there are added 75 ml of dichloromethane and 2.5 ml 1,2,3-propanetriol. 10 g of polyethylene glycol is molten and dissolved in 75 ml of dichloromethane. The latter solution is added to the former and then there are added 2.5 g of magnesium octadecanoate, 5 g of polyvinylpyrrolidone and 30 ml of concentrated colour suspension (Opaspray K-1-2109®) and the whole is homogenated. The tablet cores are coated with the thus obtained mixture in a coating apparatus.

Example 15 : Injectable solutions

[0060] 1.8 g methyl 4-hydroxybenzoate and 0.2 g propyl 4-hydroxybenzoate are dissolved in about 0.5 l of boiling water for injection. After cooling to about 50°C there are added while stirring 4 g lactic acid, 0.05 g propylene glycol and 1 g of the A.I.. The solution is cooled to room temperature and supplemented with water for injection q.s. ad 1 l volume, giving a solution of 1 mg A.I. per ml. The solution is sterilized by filtration (U.S.P. XVII p. 811) and filled in sterile containers.


Claims

1. A compound having the formula



a pharmaceutically acceptable acid addition salt or a stereochemically isomeric form thereof, wherein


Alk represents C₁₋₄alkanediyl,
D is a bicyclic heterocycle of formula



wherein


R¹ represents C₁₋₄alkyl or hydroxyC₁₋₄alkyl;
each R² represents hydrogen or C₁₋₄alkyl;
R³ represents C₁₋₄alkyl, hydroxyC₁₋₄alkyl or methyl substituted with phenyl, 5-methyl-2-furanyl or 3-pyridinyl;
and
R⁴ represents C₁₋₃alkyl, phenyl, 5-methyl-2-furanyl or 3-pyridinyl.

2. A compound according to claim 1 wherein D represents a bicyclic heterocycle of formula (b) or (c).
3. A compound according to claim 1 wherein D represents a bicyclic heterocycle of formula (a).
4. A compound according to claim 3 wherein Alk is 1,2-ethanediyl and R¹ is C₁₋₄alkyl.
5. A compound according to claim 1 wherein the compound is 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidinyl]ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-one or a pharmaceutically acceptable acid addition salt thereof.
6. A pharmaceutical composition comprising an inert carrier and as an active ingredient an effective antipsychotic amount of a compound as claimed in any of claims 1 and 5.
7. A method of preparing a pharmaceutical composition as claimed in claim 6, characterized in that a therapeutically effective amount of a compound as claimed in any of claims 1 to 5 is intimately mixed with a pharmaceutical carrier.
8. A compound as claimed in any of claims 1 to 5 for use as a medicine.
9. A process of preparing a compound as claimed in any of claims 1 to 5, characterized by
- a) N-alkylating a piperidine of formula




with an alkylating reagent of formula D-Alk-W (III) wherein W represents a reactive leaving group and D and Alk are as defined under formula (I) and R¹ may also represent a protected hydroxyC₁₋₄alkyl group, in a reaction-inert solvent; and, if necessary deprotecting the protected hydroxyC₁₋₄alkyl group by hydrogenolysis or hydrolysis;

b) cyclizing an oxime of formula




wherein D and Alk are as defined under formula (I) and Y represents a reactive leaving group, in a reaction-inert solvent;

c) cyclizing an activated oxime derivative of formula




wherein -O-L represents a reactive leaving group, at an elevated temperature, optionally in the presence of a reaction-inert solvent and optionally in the presence of a base;


d) cyclizing a β -dicarbonyl intermediate of formula




wherein R² and Alk are as defined under formula (I) and R⁵ represents a reactive leaving group, with an aminopyridine of formula




10 wherein R¹ is as defined under formula (I); thus yielding a compound of formula



25 e) cyclizing an enamine of formula




wherein R² and Alk are as defined under formula (I) and R⁵ represents a reactive leaving group, with a reagent of formula



wherein R¹ is as defined under formula (I) and R⁵ represents a reactive leaving group; thus yielding a compound of formula

50


55



15 and further, if desired, converting a compound of formula (I) into a therapeutically active non-toxic salt by treatment with an appropriate acid or conversely, converting the salt form into the free base form with alkali; and/or preparing stereochemically isomeric forms thereof.


Patentansprüche

20 1. Verbindung der Formel



ein pharmazeutisch unbedenkliches Säureadditionssalz oder eine stereochemisch isomere Form davon, wobei

35 Alk C₁₋₄-Alkandiyyl und
D einen bicyclischen Heterocyclus der Formel




50 worin

R¹ für C₁₋₄-Alkyl oder Hydroxy-C₁₋₄-alkyl;
R² jeweils für Wasserstoff oder C₁₋₄-Alkyl;
R³ für C₁₋₄-Alkyl, Hydroxy-C₁₋₄-alkyl oder phenylsubstituiertes Methyl, 5-Methyl-2-furanyl oder 3-Pyridinyl und
R⁴ für C₁₋₃-Alkyl, Phenyl, 5-Methyl-2-furanyl oder 3-Pyridinyl steht,


55 bedeutet.

2. Verbindung nach Anspruch 1, in der D für einen bicyclischen Heterocyclus der Formel (b) oder (c) steht.


3. Verbindung nach Anspruch 1, in der D für einen bicyclischen Heterocyclus der Formel (a) steht.
4. Verbindung nach Anspruch 3, in der Alk für 1,2-Ethandiyl und R¹ für C₁₋₄-Alkyl steht.
5. Verbindung nach Anspruch 1, bei der es sich um 3-[2-[4-(6-Fluor-1,2-benzisoxazol-3-yl)-1-piperidiny]-ethyl]-2,9-dimethyl-4H-pyrido[1,2-a]pyrimidin-4-on oder ein pharmazeutisch unbedenkliches Säureadditionssalz davon handelt.
6. Pharmazeutische Zusammensetzung, enthaltend einen inerten Träger und als Wirkstoff eine antipsychotisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 und 5.
7. Verfahren zur Herstellung einer pharmazeutischen Zusammensetzung nach Anspruch 6, dadurch gekennzeichnet, daß man eine therapeutisch wirksame Menge einer Verbindung nach einem der Ansprüche 1 bis 5 innig mit einem pharmazeutischen Träger vermischt.
8. Verbindung nach einem der Ansprüche 1 bis 5 zur Verwendung als Arzneimittel.
9. Verfahren zur Herstellung einer Verbindung nach einem der Ansprüche 1 bis 5, dadurch gekennzeichnet, daß man
 - a) ein Piperidin der Formel



in einem unter den Reaktionsbedingungen inerten Lösungsmittel mit einem Alkylierungsmittel der Formel D-Alk-W (III), worin W für eine reaktive Abgangsgruppe steht, D und Alk die oben unter Formel (I) angegebene Bedeutung haben und R¹ auch für eine geschützte Hydroxy-C₁₋₄-alkylgruppe stehen kann, N-alkyliert und gegebenenfalls die geschützte Hydroxy-C₁₋₄-alkylgruppe hydrogenolytisch oder hydrolytisch entschützt;
b) ein Oxim der Formel




worin D und Alk die unter Formel (I) angegebene Bedeutung haben und Y für eine reaktive Abgangsgruppe steht, in einem unter den Reaktionsbedingungen inerten Lösungsmittel cyclisiert;
c) ein aktiviertes Oximderivat der Formel




10
 worin -O-L für eine reaktive Abgangsgruppe steht, gegebenenfalls in Gegenwart eines unter den Reaktionsbedingungen inerten Lösungsmittels und gegebenenfalls in Gegenwart einer Base bei erhöhter Temperatur cyclisiert;


15
 d) ein β -Dicarbonyl-Zwischenprodukt der Formel



30
 worin R² und Alk die unter Formel (I) angegebene Bedeutung haben und R⁵ für eine reaktive Abgangsgruppe steht, mit einem Aminopyridin der Formel




40
 worin R¹ die unter Formel (I) angegebene Bedeutung hat, zu einer Verbindung der Formel




55
 cyclisiert;


e) ein Enamin der Formel



15 worin R² und Alk die unter Formel (I) angegebene Bedeutung haben und R⁵ für eine reaktive Abgangsgruppe steht, mit einem Reagens der Formel




25 worin R¹ die unter Formel (I) angegebene Bedeutung hat und R⁵ für eine reaktive Abgangsgruppe steht, zu einer Verbindung der Formel



40 cyclisiert, und, falls weiter erwünscht, Überführen einer Verbindung der Formel (I) in ein therapeutisch wirksames nicht-toxisches Salz durch Behandlung mit einer entsprechenden Säure, oder umgekehrt Überführen einer Salzform in eine freie Basenform mit Alkali; und/oder Bereiten der stereochemisch isomeren Formen hievon.


45 Revendications

1. Composé de formule




sel d'addition à un acide pharmaceutiquement acceptable ou forme stéréochimiquement isomère de celui-ci, où

Alk représente un C₁₋₄-alcanediyle,
D est un hétérocycle bicyclique de formules




(a)



(b)

ou




(c)

dans lesquelles

R¹ représente un alkyle en C₁₋₄ ou un hydroxy-C₁₋₄-alkyle ;
chaque R² représente un hydrogène ou un alkyle en C₁₋₄ ;
R³ représente un alkyle en C₁₋₄, un hydroxy-C₁₋₄-alkyle ou un méthyle substitué par un phényle, un 5-méthyl-2-furanyle ou un 3-pyridinyle ; et
R⁴ représente un alkyle en C₁₋₃, un phényle, un 5-méthyl-2-furanyle ou un 3-pyridinyle.


2. Composé selon la revendication 1, dans lequel D représente un hétérocycle bicyclique de formule (b) ou (c).
3. Composé selon la revendication 1, dans lequel D représente un hétérocycle bicyclique de formule (a).
4. Composé selon la revendication 3, dans lequel Alk est un 1,2-éthanediyle et R¹ est un alkyle en C₁₋₄.
5. Composé selon la revendication 1, dans lequel le composé est la 3-[2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)-1-piperidiny]éthyl]-2,9-diméthyl-4H-pyrido [1,2-a]pyrimidin-4-one ou un sel d'addition à un acide pharmaceutiquement acceptable de celle-ci.
6. Composition pharmaceutique comprenant un support inerte et, en tant qu'ingrédient actif une quantité antipsychotique efficace d'un composé selon l'une quelconque des revendications 1 et 5.
7. Méthode de préparation d'une composition pharmaceutique selon la revendication 6, caractérisée en ce qu'une quantité thérapeutiquement efficace d'un composé selon l'une quelconque des revendications 1 à 5 est mélangée intimement avec un support pharmaceutique.
8. Composé selon l'une quelconque des revendications 1 à 5, destiné à être utilisé en tant que médicament.
9. Procédé de préparation d'un composé selon l'une quelconque des revendications 1 à 5, caractérisé par

a) la N-alkylation d'une pipéridine de formule




(II)


avec un réactif d'alkylation de formule D-Alk-W (III), dans laquelle W représente un groupe partant réactif et D et Alk sont tels que définis pour la formule (I) et R¹ peut également représenter un groupe hydroxy-C₁₋₄-alkyle protégé, dans un solvant inerte vis-à-vis de la réaction ; et, le cas échéant, la déprotection du groupe hydroxy-C₁₋₄-alkyle protégé par hydrogénéolyse ou hydrolyse ;
 b) la cyclisation d'un oxime de formule




dans laquelle D et Alk sont tels que définis pour la formule (I) et Y représente un groupe partant réactif, dans un solvant inerte vis-à-vis de la réaction ;
 c) la cyclisation d'un dérivé d'oxime activé de formule




dans laquelle -O-L représente un groupe partant réactif, à une température élevée, éventuellement en présence d'un solvant inerte vis-à-vis de la réaction et éventuellement en présence d'une base ;
 d) la cyclisation d'un intermédiaire β dicarbonylé de formule




dans laquelle R² et Alk sont tels que définis pour la formule (I) et R⁵ représente un groupe partant réactif, avec une aminopyridine de formule




dans laquelle R¹ est tel que défini pour la formule (I) ; en donnant ainsi lieu à un composé de formule




15 e) la cyclisation d'une énamine de formule



30 dans laquelle R² et Alk sont tels que définis pour la formule (I) et R⁵ représente un groupe partant réactif, avec un réactif de formule



40 dans laquelle R¹ est tel que défini pour la formule (I) et R⁵ représente un groupe partant réactif ; en donnant ainsi lieu à un composé de formule



55 et, si on le souhaite en outre, la conversion d'un composé de formule (I) en un sel thérapeutiquement actif et non toxique, par traitement par un acide approprié, ou, inversement, la conversion d'une forme sel en une forme base libre à l'aide d'une solution alcaline; et/ou la préparation des formes stéréochimiquement isomères de ce composé.

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.